The research team began with the human disease itself. Examining liver tissue from patients with Wilson disease, they documented a constellation of metabolic injuries: impaired antioxidant capacity, abundant markers of lipid peroxidation, and, crucially, a coordinated downregulation of two linked molecules, the nuclear receptor PPARα and its downstream target FABP1, the liver fatty acid-binding protein. The same pattern appeared in the Atp7b-deficient mouse model, the standard animal proxy for the disease, and it was visible at both the transcriptomic and proteomic levels. That consistency across species and measurement platforms suggested the pair was not an incidental casualty of liver damage but an active participant in it.

To test causality, the investigators turned to hepatocytes grown in culture and exposed them to copper. The metal accumulated in the nuclear-enriched fraction of the cells, consistent with earlier reports that excess copper impairs hepatic nuclear receptor function, and it repressed PPARα and FABP1 expression in a time-dependent manner. With the protective axis weakened, the cells became strikingly vulnerable to RSL3, a chemical tool that inhibits the lipid-repair enzyme GPX4 and thereby triggers ferroptosis. Copper exposure lowered the threshold at which RSL3 killed the cells and amplified lipid peroxidation, the biochemical signature of the ferroptotic process.

The team then ran the experiment in reverse. Silencing PPARα or FABP1 in hepatocytes reproduced the copper effect almost exactly, lowering the resistance of the cells to ferroptotic stress and boosting peroxidation. Conversely, pharmacological inhibition of ferroptosis partially rescued the copper-treated cells, confirming that the cell death pathway in play was ferroptosis rather than apoptosis or necrosis. Together, the gain-of-function and loss-of-function data make a strong argument that the PPARα–FABP1 axis is not merely correlated with copper toxicity but functionally required for hepatocyte survival under copper overload.

Why would losing FABP1 matter so much? The protein is among the most abundant in the hepatocyte cytosol, where it shuttles fatty acids and, importantly, buffers polyunsaturated fatty acids, the very lipid species most prone to peroxidation. Prior work has shown that L-FABP directly interacts with PPARα in primary hepatocytes and that the protein carries intrinsic antioxidant activity. When FABP1 levels fall, polyunsaturated fatty acids are left exposed to oxidative attack, and the resulting peroxidized phospholipids, particularly those derived from arachidonic acid, are known to be the navigational signals that steer cells toward ferroptosis.

The lipidomics evidence reinforced this mechanistic picture. By integrating previously published lipidomic datasets, the researchers found that peroxidized polyunsaturated fatty acids accumulate in Wilson disease, matching the oxylipin profiles reported in patient plasma and in mouse models of the disorder. In their own experiments, overexpressing FABP1 mitigated arachidonic acid–driven lipid peroxidation and protected cells from ferroptosis. In other words, restoring the fat-binding protein partially rebuilt the cellular firewall that copper had torn down, providing a proof of concept that the axis can be targeted therapeutically.

The clinical implications extend beyond mechanism into prognosis. The team measured hepatic FABP1 expression and circulating FABP1 levels in their patient cohort and found that both declined as disease severity increased. Lower FABP1 was associated with greater inflammatory activity and more advanced fibrosis stage, and the circulating levels showed moderate predictive value for adverse outcomes. If these findings hold up in larger and more diverse cohorts, a simple blood measurement of FABP1 could eventually complement existing tools for staging Wilson disease and flagging patients at risk of rapid progression, an appealing prospect in a condition where early diagnosis dramatically alters the trajectory.

The study also reframes a long-running debate about how copper kills liver cells. Recent literature has highlighted cuproptosis, a copper-triggered cell death mechanism involving mitochondrial protein aggregation, as a candidate explanation for copper toxicity. The new data do not settle that debate, but they add a parallel and arguably better-substantiated route: copper suppresses a nuclear receptor program, the loss of that program strips away lipid protection, and the cell slides into ferroptosis. Notably, the PPARα–FABP1–ferroptosis connection has precedent elsewhere; downregulation of the axis has been implicated in ferroptosis in IgA nephropathy and in the lipid-rich microenvironment of gastric cancer metastasis, suggesting a broadly conserved vulnerability that Wilson disease happens to exploit.

Therapeutically, the findings point in two directions. The established standard of care for Wilson disease, copper chelation and zinc therapy to block metal absorption, remains the foundation, and the new work does not challenge it. But the study suggests that patients may benefit from approaches that shore up the ferroptosis defense system directly, whether by activating PPARα, restoring FABP1, or deploying ferroptosis inhibitors, particularly during acute presentations when copper levels cannot be lowered overnight. Ferroptosis has already been implicated as an inflammatory trigger in other liver diseases, including nonalcoholic steatohepatitis, so agents that dampen lipid peroxidation could have value across a spectrum of hepatic injury, with Wilson disease as a genetically defined setting in which to test them.

Caveats remain. The rescue effects of ferroptosis inhibition were partial, indicating that copper inflicts damage through additional pathways that the PPARα–FABP1 axis does not capture. The predictive value of circulating FABP1 was moderate rather than decisive, and the clinical cohort, while ethically approved and conducted under the Declaration of Helsinki, will need expansion before biomarker claims become practice. Still, the study delivers something Wilson disease research has lacked: a coherent, experimentally validated mechanism that connects the metal, a master metabolic regulator, a fat-binding protein, and a defined mode of cell death, all anchored to measurable correlates of human disease severity. It turns a decades-old question, how copper destroys the liver, into a set of answerable, and potentially druggable, molecular problems.

Subject of Research: Copper-induced suppression of the PPARα–FABP1 axis and ferroptosis in Wilson disease

Article Title: Copper-induced suppression of the PPARα–FABP1 axis sensitizes hepatocytes to ferroptosis in Wilson disease

Article References: Li, Y., Wu, Y., Zhou, Y., Zhao, L., Xu, Z., Zhang, Y., & Zhou, N. (2026). Copper-induced suppression of the PPARα–FABP1 axis sensitizes hepatocytes to ferroptosis in Wilson disease. Journal of Molecular Medicine, 104(1), Article 119. https://doi.org/10.1007/s00109-026-02725-2

Image Credits: AI Generated

DOI: 10.1007/s00109-026-02725-2

Keywords: Wilson disease, copper overload, ferroptosis, PPARα, FABP1, lipid peroxidation, hepatocytes, liver fibrosis, ATP7B, polyunsaturated fatty acids, nuclear receptor, biomarker

Wilson disease is caused by inherited loss-of-function mutations in the ATP7B gene, which encodes a copper-transporting ATPase responsible for loading copper onto ceruloplasmin in the liver and for excreting surplus copper into bile. When ATP7B fails, dietary copper that would normally leave the body through the biliary route instead accumulates in hepatocytes, eventually spilling into the bloodstream and depositing in the brain, cornea, kidneys and other organs. Clinical presentation is notoriously variable, ranging from acute liver failure in children and young adults to tremor, dystonia, psychiatric disturbance and cognitive decline later in life. The classic Kayser-Fleischer rings in the cornea remain one of the most recognizable diagnostic signs, but the underlying cellular events that convert copper overload into organ failure have remained only partially mapped.

The review emphasizes that copper’s dual role as an essential cofactor and a potent toxin hinges on concentration and chemical speciation. In controlled amounts, copper supports enzymes involved in respiration, antioxidant defense, iron metabolism, neurotransmitter synthesis and connective tissue cross-linking. In excess, particularly in the loosely bound, labile form that accumulates when buffering proteins such as metallothioneins are overwhelmed, copper catalyzes the generation of reactive oxygen species through Fenton-like chemistry. This oxidative burst damages lipids, proteins and DNA, and it is the mitochondria, the cell’s energy factories and major sites of copper-sensitive respiratory function, that emerge as a primary battleground in the disease process.

Mitochondrial dysfunction occupies a central position in the pathogenic model the authors assemble. Copper overload impairs the respiratory chain, disrupts mitochondrial membrane potential, distorts the ultrastructure of cristae and interferes with the metabolic enzymes that carry out the citric acid cycle and oxidative phosphorylation. Studies in animal models of Wilson disease, including the toxic milk mouse and the Long-Evans Cinnamon rat, have documented mitochondrial swelling and respiratory defects that precede overt liver failure. In patients, mitochondrial abnormalities have been observed in hepatocytes and in neural tissue, providing a mechanistic bridge between the biochemical burden of copper and the energetic collapse that marks end-stage disease. Because mitochondria also serve as decision-making hubs for cell death signaling, their compromise does not merely reduce energy output; it actively initiates the programs that dismantle the cell.

Perhaps the most consequential theme in the review is the concept of regulated cell death, the family of genetically encoded, signalable demise pathways that include apoptosis, necroptosis, ferroptosis and the recently described copper-dependent process known as cuproptosis. Classical descriptions of copper toxicity in Wilson disease leaned heavily on nonspecific necrosis, but the field now recognizes that dying hepatocytes and neurons deploy ordered molecular machinery. Apoptosis, driven by mitochondrial outer membrane permeabilization and caspase activation, has been documented in copper-loaded liver tissue. Necroptosis, an inflammatory form of regulated death mediated by the RIPK1-RIPK3-MLKL axis, offers a plausible route by which copper-stressed liver tissue recruits immune cells and amplifies damage. Ferroptosis, an iron-dependent lipid peroxidation-driven death modality, is closely linked to the oxidative stress that copper overload generates, and glutathione depletion, a recurring biochemical finding in Wilson disease, removes a key cellular defense against it.

Cuproptosis deserves particular attention in this framework. Identified as a distinct form of regulated cell death, it depends on copper binding to lipoylated components of the tricarboxylic acid cycle, causing those proteins to aggregate and triggering proteotoxic stress that culminates in cell death. Because the pathway is intrinsically mitochondrial and metabolic, it connects the two other pillars of the review’s thesis: copper excess and mitochondrial dysfunction. Whether cuproptosis is the dominant death pathway in Wilson disease hepatocytes or one contributor among several remains an open question, and the authors are careful to frame it as a hypothesis-generating link rather than a settled fact. Still, the convergence is striking. A disease defined by copper retention, a cell death modality defined by copper sensitivity, and an organelle whose failure characterizes both.

The neurological dimension of Wilson disease adds another layer of complexity. The brain is exquisitely sensitive to metal imbalance, and copper accumulation in the basal ganglia and other regions contributes to the movement disorders and neuropsychiatric symptoms that define the neurologic form of the illness. Neurons face the same oxidative and mitochondrial threats as hepatocytes, but with less regenerative capacity and with additional vulnerabilities, including disruption of copper-dependent enzymes involved in neurotransmitter metabolism and myelination. The review highlights how glial cells, particularly astrocytes, participate in copper handling in the brain and how their dysfunction may propagate injury to neurons. Understanding whether the same regulated death pathways operate in neural tissue as in the liver is an important direction for future research, with direct implications for the roughly half of patients who present with or develop neurological disease.

Therapeutically, the framework has immediate relevance. Standard treatment for Wilson disease has rested for decades on two strategies: chelation therapy with drugs such as penicillamine and trientine, which bind copper and promote its urinary excretion, and zinc salts, which block intestinal copper absorption and induce metallothionein in enterocytes. These approaches are effective for many patients but are limited by side effects, the risk of neurological worsening during initial chelation, and the irreversibility of some established damage. The review’s synthesis suggests new targets. If mitochondrial dysfunction is a proximate driver of cell death, then mitochondria-protective agents, antioxidants and modulators of mitochondrial quality control could complement copper-lowering therapy. If specific death pathways such as necroptosis or ferroptosis are activated, their molecular regulators become candidate drug targets, an approach already being explored in other liver diseases. The authors also point to gene therapy and mRNA-based strategies aimed at restoring functional ATP7B, several of which are in preclinical and early clinical development, as interventions that address the root cause rather than downstream consequences.

Biomarker development is another area the review identifies as ripe for progress. Current monitoring relies on serum copper and ceruloplasmin, 24-hour urinary copper excretion and non-ceruloplasmin-bound copper measurements, none of which perfectly reflect intracellular copper burden or the activity of the death pathways that matter most in tissue. Reliable markers of mitochondrial injury, lipid peroxidation or regulated cell death activation in accessible biofluids would allow clinicians to gauge disease activity more precisely and to evaluate new therapies more efficiently. Research into copper-sensitive probes and imaging approaches may eventually permit noninvasive assessment of metal distribution in liver and brain, transforming both diagnosis and treatment monitoring.

The broader significance of the review extends beyond a single rare disease. Wilson disease has historically served as a model for understanding copper biology in general, and insights gained from it inform research on common conditions in which copper dysregulation has been implicated, including neurodegenerative disorders, cancer and non-alcoholic fatty liver disease. The recognition that metals can execute cells through dedicated death pathways has opened a field that now spans toxicology, cell biology and therapeutics. By situating Wilson disease within this landscape, the authors argue that the condition should be viewed not merely as a storage disorder to be drained, but as a systems-level failure of metal homeostasis, mitochondrial integrity and cell death control. For patients, the hope is that this integrated view will accelerate the translation of molecular discoveries into treatments that protect cells before the point of no return is crossed, preserving both liver function and the neurological health on which quality of life depends.

Subject of Research: Copper dyshomeostasis, mitochondrial dysfunction and regulated cell death pathways in Wilson disease

Article Title: Copper dyshomeostasis, mitochondrial dysfunction, and regulated cell death in Wilson disease

Article References: Qian, N., Xi, H., Song, Y., Li, J., Yang, Y., Rao, Z., Zhai, S., He, W., Qin, G., Cheng, T., & Yang, W. (2026). Copper dyshomeostasis, mitochondrial dysfunction, and regulated cell death in Wilson disease. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03361-y

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03361-y

Keywords: Wilson disease, copper dyshomeostasis, ATP7B, mitochondrial dysfunction, cuproptosis, regulated cell death, apoptosis, necroptosis, ferroptosis, hepatic copper accumulation, chelation therapy, gene therapy